Journal of Biological Chemistry · 2005 · 83 citations · 40 references
MedicineMolecular BiologyOncologyGene ExpressionMolecular OncologyTranscriptional RegulationAntitumor AntibioticsCancer Cell SignalingAnticancer ActivityDna Binding SitesDrug Resistance ModulationSurvivin InhibitionTranscriptional RepressionTranscriptional Repression Mechanisms
Expression of the antiapoptotic protein survivin is associated with cancer cell viability and drug resistance. Thus, control of its expression in cancer cells has significant consequences for cancer therapeutics. Here we have shown that hedamycin, a GC-rich DNA binding drug, down-regulated survivin expression. Using a series of survivin promoter-luciferase constructs, we have identified an 86-bp GC-rich DNA element (-124 to -39) that mediates the ability of hedamycin to down-regulate survivin expression. Furthermore, both in vivo foot-printing and in vitro gel mobility shift experiments revealed that hedamycin bound to a 21-bp GC-rich DNA element (-115 to -95) in the survivin promoter. This drug-DNA interaction abrogated the binding of Sp-1 or Sp1-like proteins to the 21-bp cis-acting DNA element, and mutagenesis of this region consistently diminished survivin promoter activity. Finally, down-regulation of survivin transcription by hedamycin modulated the viability of cancer cells. These data suggest that abrogation of Sp-1 or Sp1-like protein binding to the 21-bp DNA element in the survivin promoter contributes at least in part to the inhibitory effect of hedamycin on survivin gene transcription. Drug-induced modulation of survivin gene expression may provide novel approaches for cancer therapeutics. Expression of the antiapoptotic protein survivin is associated with cancer cell viability and drug resistance. Thus, control of its expression in cancer cells has significant consequences for cancer therapeutics. Here we have shown that hedamycin, a GC-rich DNA binding drug, down-regulated survivin expression. Using a series of survivin promoter-luciferase constructs, we have identified an 86-bp GC-rich DNA element (-124 to -39) that mediates the ability of hedamycin to down-regulate survivin expression. Furthermore, both in vivo foot-printing and in vitro gel mobility shift experiments revealed that hedamycin bound to a 21-bp GC-rich DNA element (-115 to -95) in the survivin promoter. This drug-DNA interaction abrogated the binding of Sp-1 or Sp1-like proteins to the 21-bp cis-acting DNA element, and mutagenesis of this region consistently diminished survivin promoter activity. Finally, down-regulation of survivin transcription by hedamycin modulated the viability of cancer cells. These data suggest that abrogation of Sp-1 or Sp1-like protein binding to the 21-bp DNA element in the survivin promoter contributes at least in part to the inhibitory effect of hedamycin on survivin gene transcription. Drug-induced modulation of survivin gene expression may provide novel approaches for cancer therapeutics. Survivin is a unique member of the inhibitor of apoptosis family of proteins (1Salvesen G.S. Duckett C.S. Nat. Rev. Mol. Cell. Biol. 2002; 3: 401-410Crossref PubMed Scopus (1581) Google Scholar, 2Liston P. Fong W.G. Korneluk R.G. Oncogene. 2003; 22: 8568-8580Crossref PubMed Scopus (390) Google Scholar, 3Li F. J. Cell. Physiol. 2003; 197: 8-29Crossref PubMed Scopus (307) Google Scholar, 4Altieri D.C. Oncogene. 2003; 22: 8581-8589Crossref PubMed Scopus (827) Google Scholar). It is highly expressed in various cancers but is undetectable in most normal adult tissues (5Ambrosini G. Adida C. Altieri D.C. Nat. Med. 1997; 3: 917-921Crossref PubMed Scopus (3025) Google Scholar). Current studies indicate that the expression of survivin in cancer cells is associated with cancer progression, poor prognosis, drug resistance, and short patient survival (3Li F. J. Cell. Physiol. 2003; 197: 8-29Crossref PubMed Scopus (307) Google Scholar). Functionally, survivin is involved in the control of apoptosis (6Li F. Ambrosini G. Chu E.Y. Plescia J. Tognin S. Marchisio P.C. Altieri D.C. Nature. 1998; 396: 580-584Crossref PubMed Scopus (1747) Google Scholar) and the regulation of cell division (7Li F. Ackermann E.J. Bennett C.F. Rothermel A.L. Plescia J. Tognin S. Villa A. Marchisio P.C. Altieri D.C. Nat. Cell Biol. 1999; 1: 461-466Crossref PubMed Scopus (554) Google Scholar). Consistent with the dual functions of survivin, there are two pools (cytoplasmic and nuclear) of survivin associated with distinct subcellular components (8Fortugno P. Wall N.R. Giodini A. O'Connor D.S. Plescia J. Padgett K.M. Tognin S. Marchisio P.C. Altieri D.C. J. Cell Sci. 2002; 115: 575-585PubMed Google Scholar). Moreover, the expression of survivin is cell cycle-regulated with a robust increase in G2/M (6Li F. Ambrosini G. Chu E.Y. Plescia J. Tognin S. Marchisio P.C. Altieri D.C. Nature. 1998; 396: 580-584Crossref PubMed Scopus (1747) Google Scholar, 9Li F. Altieri D.C. Cancer Res. 1999; 59: 3143-3151PubMed Google Scholar). It has been demonstrated that inhibition of survivin expression or interference of survivin function, including survivin antisense oligonucleotides (7Li F. Ackermann E.J. Bennett C.F. Rothermel A.L. Plescia J. Tognin S. Villa A. Marchisio P.C. Altieri D.C. Nat. Cell Biol. 1999; 1: 461-466Crossref PubMed Scopus (554) Google Scholar, 10Olie R.A. Simoes-Wust A.P. Baumann B. Leech S.H. Fabbro D. Stahel R.A. Zangemeister-Wittke U. Cancer Res. 2000; 60: 2805-2809PubMed Google Scholar, 11Chen J. Wu W. Tahir S.K. Kroeger P.E. Rosenberg S.H. Cowsert L.M. Bennett F. Krajewski S. Krajewska M. Welsh K. Reed J.C. Ng S.C. Neoplasia. 2000; 2: 235-241Crossref PubMed Scopus (184) Google Scholar, 12Jiang X. Wilford C. Duensing S. Munger K. Jones G. Jones D. J. Cell. Biochem. 2001; 83: 342-354Crossref PubMed Scopus (66) Google Scholar, 13Xia C. Xu Z. Yuan X. Uematsu K. You L. Li K. Li L. McCormick F. Jablons D.M. Mol. Cancer Ther. 2002; 1: 687-694PubMed Google Scholar, 14Ansell S.M. Arendt B.K. Grote D.M. Jelinek D.F. Novak A.J. Wellik L.E. Remstein E.D. Bennett C.F. Fielding A. Leukemia. 2004; 18: 616-623Crossref PubMed Scopus (87) Google Scholar, 15.Younis, T., Ramnath, N., Ling, X., Bernacki, R. J., and Li, F. (2004) The Proceedings of the Association for Cancer Research 95th Annual Meeting, Orlando, FL, March 27–31, 2004, Vol. 45, pp. 697-698, AACR, Orlando, FloridaGoogle Scholar) or survivin antisense expression vectors (16Ambrosini G. Adida C. Sirugo G. Altieri D.C. J. Biol. Chem. 1998; 273: 11177-11182Abstract Full Text Full Text PDF PubMed Scopus (433) Google Scholar, 17Grossman D. McNiff J.M. Li F. Altieri D.C. J. Investig. Dermatol. 1999; 113: 1076-1081Abstract Full Text Full Text PDF PubMed Scopus (349) Google Scholar, 18Grossman D. McNiff J.M. Li F. Altieri D.C. Lab. Investig. 1999; 79: 1121-1126PubMed Google Scholar, 19Kanwar J.R. Shen W.P. Kanwar R.K. Berg R.W. Krissansen G.W. J. Natl. Cancer Inst. 2001; 93: 1541-1552Crossref PubMed Scopus (167) Google Scholar, 20Yamamoto T. Manome Y. Nakamura M. Tanigawa N. Eur. J. Cancer. 2002; 38: 2316-2324Abstract Full Text Full Text PDF PubMed Scopus (64) Google Scholar, 21Tu S.P. Jiang X.H. Lin M.C. Cui J.T. Yang Y. Lum C.T. Zou B. Zhu Y.B. Jiang S.H. Wong W.M. Chan A.O. Yuen M.F. Lam S.K. Kung H.F. Wong B.C. Cancer Res. 2003; 63: 7724-7732PubMed Google Scholar), RNA interference (22Ling X. Li F. BioTechniques. 2004; 36 (456-460): 450-454Crossref PubMed Google Scholar), ribozymes (23Pennati M. Colella G. Folini M. Citti L. Daidone M.G. Zaffaroni N. J. Clin. Investig. 2002; 109: 285-286Crossref PubMed Scopus (112) Google Scholar, 24Pennati M. Binda M. Colella G. Folini M. Citti L. Villa R. Daidone M.G. Zaffaroni N. J Investig. Dermatol. 2003; 120: 648-654Abstract Full Text Full Text PDF PubMed Scopus (100) Google Scholar, 25Choi K.S. Lee T.H. Jung M.H. Cancer Gene Ther. 2003; 10: 87-95Crossref PubMed Scopus (75) Google Scholar, 26Pennati M. Binda M. Colella G. Zoppe M. Folini M. Vignati S. Valentini A. Citti L. De Cesare M. Pratesi G. Giacca M. Daidone M.G. Zaffaroni N. Oncogene. 2004; 23: 386-394Crossref PubMed Scopus (96) Google Scholar), triplex DNA formation (27Shen C. Buck A. Polat B. Schmid-Kotsas A. Matuschek C. Gross H.J. Bachem M. Reske S.N. Cancer Gene Ther. 2003; 10: 403-410Crossref PubMed Scopus (42) Google Scholar), survivin dominant-negative mutants (7Li F. Ackermann E.J. Bennett C.F. Rothermel A.L. Plescia J. Tognin S. Villa A. Marchisio P.C. Altieri D.C. Nat. Cell Biol. 1999; 1: 461-466Crossref PubMed Scopus (554) Google Scholar, 21Tu S.P. Jiang X.H. Lin M.C. Cui J.T. Yang Y. Lum C.T. Zou B. Zhu Y.B. Jiang S.H. Wong W.M. Chan A.O. Yuen M.F. Lam S.K. Kung H.F. Wong B.C. Cancer Res. 2003; 63: 7724-7732PubMed Google Scholar, 28O'Connor D.S. Grossman D. Plescia J. Li F. Zhang H. Villa A. Tognin S. Marchisio P.C. Altieri D.C. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 13103-13107Crossref PubMed Scopus (591) Google Scholar), and pharmacological inhibitors of Cdc2 (29O'Connor D.S. Wall N.R. Porter A.C. Altieri D.C. Cancer Cells. 2002; 2: 43-54Abstract Full Text Full Text PDF PubMed Scopus (294) Google Scholar, 30Wall N.R. O'Connor D.S. Plescia J. Pommier Y. Altieri D.C. Cancer Res. 2003; 63: 230-235PubMed Google Scholar), induces cancer cell death. Thus, survivin appears to be an important cancer therapeutic target, and modulation of survivin expression and/or function may provide rational approaches for cancer therapeutics. One of the major strategies for modulating survivin expression is control of its transcription. We and others have previously demonstrated that doxorubicin-induced cancer cell death is at least in part involved in the transcriptional inhibition of survivin through doxorubicin stabilization of p53 proteins (31Zhou M. Gu L. Li F. Zhu Y. Woods W.G. Findley H.W. J. Pharmacol. Exp. Ther. 2002; 303: 124-131Crossref PubMed Scopus (127) Google Scholar, 32Mirza A. McGuirk M. Hockenberry T.N. Wu Q. Ashar H. Black S. Wen S.F. Wang L. Kirschmeier P. Bishop W.R. Nielsen L.L. Pickett C.B. Liu S. Oncogene. 2002; 21: 2613-2622Crossref PubMed Scopus (498) Google Scholar, 33Hoffman W.H. Biade S. Zilfou J.T. Chen J. Murphy M. J. Biol. Chem. 2002; 277: 3247-3257Abstract Full Text Full Text PDF PubMed Scopus (710) Google Scholar). However, it is not known whether small sequence-selective DNA binding anticancer agents could modulate survivin expression by binding to the survivin promoter region and regulating promoter activity. Also, it is not known whether the modulation of survivin transcription by certain DNA binding drugs plays a role in drug action mechanism associated with induction of tumor cell death. Answers to these questions could lead to the development of novel approaches to control survivin transcription for new cancer therapeutic strategies. In this report, we investigated the molecular specificity of a GC-rich sequence-selective DNA binding drug, hedamycin. We found that hedamycin down-regulates survivin transcription by engaging an 86-bp GC-rich element (-124 to -39) in the survivin core promoter region and by preventing accessibility of this sequence to Sp1 or Sp1-like proteins involved in transcription. Functionally, hedamycin-induced down-regulation of survivin resulted in enhanced apoptosis of tumor cells. Cell Culture and Reagents—Cells from human colon cancer (HCT116) and cervical epithelial carcinoma (HeLa) were maintained in RPMI1640 and DMEM, 1The abbreviations used are: DMEM, Dulbecco's modified Eagle's medium; LM-PCR, ligation-mediated PCR; EMSA, electrophoretic gel mobility shift assay; PBS, phosphate-buffered saline; EGFP, enhanced green fluorescent protein; DMS, dimethyl sulfate. respectively, supplemented with 10% fetal bovine serum (Mediatech Cellgro, Herndon, VA), 100 units/ml of penicillin, and 0.1 μg/ml of streptomycin (Invitrogen) in a humid atmosphere incubator with 5% CO2 at 37 °C. Cells were routinely subcultured twice weekly. The antisurvivin antibody (FL-142), a polyclonal rabbit IgG antibody generated by immunizing rabbits with the full-length survivin protein, was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Hedamycin was obtained from the NCI, National Institutes of Health. Propidium iodide, dimethyl sulfate (DMS), piperidine, monoclonal antiactin antibody, and goat peroxidase-conjugated antirabbit IgG antibody were purchased from Sigma. The dual-luciferase reporter assay system and T4 DNA ligase were purchased from Promega (Madison, WI). Vent DNA polymerase and restriction enzymes were from New England Biolab (Beverly, MA). Oligotransfectamine™ reagent and Lipofectamine™ 2000 reagents were purchased from Invitrogen. Western Blot—In all experiments, cells were treated with hedamycin in the presence of complete medium containing 10% serum. Western blot analysis of survivin and actin expression was performed as described previously X. M.G. Li F. J. Biol. Chem. 2004; Full Text Full Text PDF PubMed Scopus Google Scholar). were a system and by various RNA and both with and hedamycin were used to The for survivin and were by blot analysis as described previously F. X. H. L. P. Wu J. L. M.G. Oncogene. 2004; Scholar). and cells were in and to for of the survivin promoter-luciferase F. Altieri D.C. Biochem. J. 1999; PubMed Scopus Google Scholar) was with cells. of a and of in of were with of Lipofectamine™ in of in a for of at for the was to containing of for the was by complete medium containing 10% serum. Cells were treated with hedamycin and for drug the a dual-luciferase reporter assay system was The cells in were with and with to on a for to at Cell was used for of in a by the cell with of assay reagent for and of reagent for activity. were to as of the Survivin of from to in was an system was with in with of DNA and with for at 37 °C. of the for at the DNA was and with by a and DNA was at in of containing and of from the were with the containing and The from were for at with of and and for at °C. DNA at were with of for at 37 and in a containing 5% and of T4 at cells were with the DNA by The from the were identified by of from The in containing the was by In by was on the and B. R. K. Current in New Scholar) with cells in with or hedamycin were for with of containing of DMS, by of for with of Cells were with of and The were at 37 for and with of The DNA in the was with an of in of and with of in the presence of The DNA was in of and to a of DNA in of from cells drug was with of in for and with of and DNA in of from cells treated with hedamycin was with of DNA from was by of and with The DNA was in for at for on and for in a DNA was in of containing by of and a in of containing by of with of DNA was in of in a and in to a of for of the two and were of DNA were used for the with or to for sequence and Vent DNA by of the to the DNA at T4 DNA The DNA in was with in the presence of and of and with This DNA was used as for and or to with Vent DNA polymerase for by two or The DNA in was an of and the was The DNA in was with of with and for of the was in of and at for We of on a gel with of Cell cells at were and the at at for the cell were with cell of 100 units/ml and Cells were as and in cell of with The cells were to for on Cell were by for at and with in 100 units/ml and The cell was on for with The were by at for at °C. The were in and at for were at the with T4 were in the binding 0.1 bovine serum 10% 0.1 μg/ml μg/ml for at in a of with and an of in the presence or of hedamycin. of of DNA the was for an at °C. was the of a gel and at in at for the interaction of the 21-bp DNA element to for sequence with hedamycin, the was on a of a were and by The sequence for Sp-1 binding used in this is of in the 21-bp element in the was generated as Using as the was a of and and the 21-bp element in with and the was the reporter at the and in the of the reporter The obtained were by and and by of the Survivin Expression and Cell expression for survivin has been previously (6Li F. Ambrosini G. Chu E.Y. Plescia J. Tognin S. Marchisio P.C. Altieri D.C. Nature. 1998; 396: 580-584Crossref PubMed Scopus (1747) Google Scholar, 17Grossman D. McNiff J.M. Li F. Altieri D.C. J. Investig. Dermatol. 1999; 113: 1076-1081Abstract Full Text Full Text PDF PubMed Scopus (349) Google Scholar). cells were in for studies or in for Cells at were with or survivin expression for of DNA in 100 for of was with for of Lipofectamine™ 2000 in 100 for of in a for of a the was at for the 2000 was to containing of the cell The 2000 was by complete medium containing 10% serum for Cells were treated with hedamycin Cells were with containing for containing and with cells from the were by and with Cells were in of for and in of containing μg/ml and μg/ml for on Cells were by by with and from were were performed a of with a control to the data were we a to the to We a The are and was at the of Hedamycin Survivin Expression and investigated the ability of hedamycin, a GC-rich binding drug to expression of the and apoptosis of cancer cell including and with hedamycin resulted in significant inhibition of survivin expression. of hedamycin were associated with of cancer cell a Hedamycin was associated with down-regulation of survivin expression a transcriptional mechanism for the modulation of survivin expression. reporter assay experiments revealed that hedamycin survivin promoter down-regulates survivin expression and its promoter cells were treated as survivin expression was by expression was an control for RNA cells were with a survivin promoter-luciferase and the control Cells were treated with hedamycin for as by of a dual reporter system as described were from a in to and are shown in a as is the 86-bp DNA the Survivin the of Hedamycin on Survivin the mechanism by hedamycin down-regulates survivin promoter a series of survivin promoter-luciferase previously F. Altieri D.C. Biochem. J. 1999; PubMed Scopus Google Scholar) were cells and for transcriptional with hedamycin for to shown in a survivin core promoter region was to the inhibitory effect of hedamycin on survivin gene expression. we the region in the survivin promoter a of from the core promoter In these experiments, a cis-acting DNA element involved in transcriptional was to an 86-bp GC-rich DNA to -39) of the 86-bp promoter region revealed a significant of promoter was not investigated for 21-bp DNA the 86-bp DNA at in in the of Hedamycin on Survivin whether a cis-acting DNA element was for down-regulation of survivin gene we an in vivo In these experiments, a DNA element containing a 21-bp DNA and to that the binding of hedamycin to DNA the of with enhanced of DNA to Consistent with this experiments revealed that hedamycin bound to the 21-bp DNA and and that the interaction in the 21-bp DNA element from to -95) was in the presence of hedamycin In experiments, the was by Sp-1 but not by DNA an DNA that Sp-1 or proteins were involved in binding to the 21-bp binding the to Sp-1 in the 21-bp the specificity of the DNA binding element, mutagenesis experiments were shown in the 21-bp DNA element in the survivin core promoter resulted in survivin promoter In a of the human revealed that the 21-bp GC-rich was highly in the promoter region of human as as in the of an human a role of this DNA element in of transcriptional of interaction by the binding of hedamycin to the 21-bp DNA element its interaction with The of with hedamycin, and DNA are Sp-1 and but not DNA an DNA with the core was by in the and were cells. was were as described in are the from a performed in Expression of Survivin the of Hedamycin on the of Cell whether down-regulation of survivin expression a role in cell we expressed survivin in cells and in hedamycin-induced cell death. In these experiments, of survivin hedamycin-induced cell death as with cells and The role of survivin in hedamycin-induced cell death was by and expression of survivin the of cells DNA in to hedamycin as with cells and studies have on the role of various sequence-selective DNA binding drugs for ability to DNA 2000; 1: PubMed Scopus Google Scholar, T. Mol. Cancer Ther. 2004; 3: Google Scholar, Nat. Rev. Cancer. 2002; 2: PubMed Scopus Google Scholar), is known these drugs gene transcription and whether gene transcription inhibition contributes to cell inhibition and/or cell death. Moreover, it is not known whether survivin plays a role in induction of cell death by these of In this we the of hedamycin on the regulation of survivin gene expression. We found that hedamycin inhibitory on survivin protein, and promoter and and that this at least in to cancer cell death and activity. We and others have previously demonstrated that the cancer therapeutic drug doxorubicin down-regulates survivin expression by a transcriptional mechanism (31Zhou M. Gu L. Li F. Zhu Y. Woods W.G. Findley H.W. J. Pharmacol. Exp. Ther. 2002; 303: 124-131Crossref PubMed Scopus (127) Google Scholar, 32Mirza A. McGuirk M. Hockenberry T.N. Wu Q. Ashar H. Black S. Wen S.F. Wang L. Kirschmeier P. Bishop W.R. Nielsen L.L. Pickett C.B. Liu S. Oncogene. 2002; 21: 2613-2622Crossref PubMed Scopus (498) Google Scholar, 33Hoffman W.H. Biade S. Zilfou J.T. Chen J. Murphy M. J. Biol. Chem. 2002; 277: 3247-3257Abstract Full Text Full Text PDF PubMed Scopus (710) Google Scholar). However, the transcriptional of survivin by doxorubicin an mechanism that stabilization of p53 protein, in to the the survivin core promoter region to its transcription a mechanism for drug However, whether DNA binding agents modulate survivin transcription through a cis-acting mechanism not been previously In this we the sequence-selective DNA binding drug hedamycin, with GC-rich DNA to its modulation of survivin gene transcription. Consistent with the DNA binding of hedamycin, we have identified a highly GC-rich cis-acting DNA element the GC-rich core promoter region of survivin that is for the inhibitory effect of hedamycin on survivin promoter In vivo and in vitro experiments have identified a DNA element from to -95) to hedamycin Hedamycin binding to the 21-bp DNA element abrogated the interaction and Moreover, the was by but not by DNA oligonucleotides that the proteins in the are Sp-1 or Sp1-like in the 21-bp DNA element survivin promoter in the assay these suggest that the 21-bp DNA is at least involved in the effect of hedamycin on inhibition of survivin promoter activity. These may not be to modulation of the survivin promoter and may a mechanism of transcriptional sequence of the human that the 21-bp DNA element used in the is highly in the promoter region of human including the transcription D.S. P. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar), protein P. H. J.C. L. 2002; PubMed Scopus Google Scholar), and C. Lam A. De K. Oncogene. 2003; 22: PubMed Scopus Google Scholar). the 21-bp element identified is highly in the of human including the of is involved in transcriptional control of gene and the human was shown to be in of H. J.M. M. M. Reed PubMed Scopus Google Scholar). this is the to at the molecular a transcriptional control of survivin expression by a sequence-selective DNA binding This may have for novel anticancer as survivin by transcriptional or has been consistently associated with of cell and of apoptosis in a of tumor cell It be that studies of DNA binding drugs on DNA and modulation by the DNA binding drugs as in as and/or cell as reporter gene the serum element from the gene promoter A. 2000; PubMed Scopus Google Scholar, A.L. 2002; PubMed Scopus Google Scholar) or DNA J. Biol. Chem. Full Text PDF PubMed Google Scholar, J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar) were previously used as of this is that the DNA may not be the most for a sequence-selective DNA binding we have used a on reporter analysis to cis-acting DNA involved in drug action and the and modulation of drug action both in vivo and in vitro approaches The of these was by the ability of survivin to hedamycin-induced cell down-regulation of survivin as of the of the of hedamycin In we have a novel survivin gene expression in to the DNA binding drug hedamycin. The described may have for of transcriptional control by DNA binding drugs and may the for therapeutic strategies at survivin gene expression in tumor in We from the for with the of the data in this
40
Control of apoptosis and mitotic spindle checkpoint by survivin
Fengzhi Li, Grazia Ambrosini, Emily Chu et al. · Nature · 1998 · 1.9K citations
Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53
William H. Hoffman, S. Biade, Jack T. Zilfou et al. · Journal of Biological Chemistry · 2002 · 788 citations · Full text
Life Sciences, Genetics, Oncology +16